Abstract
Microphthalmia transcription factor (MITF) is an established melanocytic marker originally credited with a high degree of specificity. We report a series of 11 atypical fibroxanthoma (AFX) from 2 laboratories showing positive MITF staining. Although there are multiple case reports illustrating MITF staining in a range of tumors, aberrant staining in AFX has not been previously reported. Awareness of the possibility of MITF positivity in AFX is important to avoid a misdiagnosis of melanoma. We also report positive MITF staining in 2 nonneural granular cell tumors and discuss the overlap with the granular subtype of AFX.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Biomarkers, Tumor / analysis
-
Biopsy
-
Diagnostic Errors / prevention & control
-
Female
-
Fibroma / chemistry*
-
Fibroma / etiology
-
Fibroma / pathology
-
Humans
-
Immunohistochemistry
-
Male
-
Melanoma / chemistry
-
Melanoma / pathology
-
Microphthalmia-Associated Transcription Factor / analysis*
-
Middle Aged
-
Neoplasms, Radiation-Induced / chemistry*
-
Neoplasms, Radiation-Induced / etiology
-
Neoplasms, Radiation-Induced / pathology
-
New Zealand
-
Predictive Value of Tests
-
Skin Neoplasms / chemistry*
-
Skin Neoplasms / etiology
-
Skin Neoplasms / pathology
-
Sunlight / adverse effects
Substances
-
Biomarkers, Tumor
-
MITF protein, human
-
Microphthalmia-Associated Transcription Factor